Publication

Comparison of the prevalence of advanced fibrosis (AF) using two combinations: Liver stiffness measurement (LSM or VCTE Fibroscan) along with LIVERSTAT (LST) or FIB-4 in a prospective chronic liver diseases (CLD) cohort

aida / November 6, 2024

AI-based blood tests LIVERSTAT for advanced fibrosis (AF) in patients with T2D can streamline the diagnostic process. Aim of this […]

Publication

Combination of LIVERFASt (LF) & Liver Stiffness Measurement (LSM) using Fibroscan outperforms FIB-4 & LSM, for the identification of MASLD advanced fibrosis (AF) in patients with type 2 diabetes (T2D)

aida / November 6, 2024

The study aims to compare retrospectively two combinations for one-step assessment of advanced fibrosis: LIVERFASt Fibrosis & Liver Stiffness Measurement

Publication

Application of LIVERFASt to Predict Steatosis in Chronic Hepatitis B Patients with Metabolic Syndrome

aida / July 6, 2024

Aims for the study: To evaluate the prognostic values of LIVERFASt as a noninvasive biomarker in detecting hepatic steatosis in

← Previous 1 2

US Headquarters

615 Baronne St, Suite 100 New Orleans LA 70113
1-888-552-1603

Asia Headquarters

79 Science Park Drive, Cintech IV, #06-01/08 Singapore 118264
+ 65 6817 6290
service@fibronostics.com

For Clinicians

LIVERFASt™
LIVERSTAT
How it Works
Benefits

For Patients

Overview
Risk Groups
Prevalence
Early Detection

Our Technology

How It Works
Key Features
Benefits
Scientific Basis and Clinical Validation

About Us

Testimonials
Who Are We
Scientific Advisors
Our Team

Resources

News
Blog
Publications
Trust Center

Privacy Policy
Cookie Policy
Terms of Use

Scroll to Top